VIII Евразийский конгресс кардиологов. Легочная гипертензия или высший пилотаж кардиологии - Журнал Системные Гипертензии Том 17, №2 (2020)
VIII Евразийский конгресс кардиологов. Легочная гипертензия или высший пилотаж кардиологии
VIII Евразийский конгресс кардиологов. Обзор симпозиумов. Легочная гипертензия или высший пилотаж кардиологии. Системные гипертензии. 2020; 17 (2): 66–68. DOI:10.26442/2075082X.2020.2.200213
DOI: 10.26442/2075082X.2020.2.200213
________________________________________________
DOI: 10.26442/2075082X.2020.2.200213
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Пандемия COVID-19, нарушив привычное течение жизни, внесла определенные коррективы и в работу научного медицинского сообщества. Благодаря современным технологиям обмен профессиональной информацией не останавливается, он лишь принимает новые формы: конгрессы, конференции, мастер-классы проходят в онлайн-режиме. Предлагаем читателям материалы, подготовленные по докладам, представленным на VIII Евразийском конгрессе кардиологов, прошедшем онлайн 27–28 мая 2020 г.
Список литературы
1. Чазова И.Е. и др. Клинические рекомендации по диагностике и лечению легочной гипертензии. Евразийская ассоциация кардиологов. 2019 г. http://cardio-eur.asia/media/files/clinical_recommendations/Klinicheskiye_rekomendatsii_Yevraziyskoy...
[Chazova I.E. et al. Clinical recommendations for the diagnosis and treatment of pulmonary hypertension. Eurasian Association of Cardiology. 2019 year. http://cardio-eur.asia/media/files/clinical_recommendations/Klinicheskiye_rekomendatsii_Yevraziyskoy... (in Russian).]
2. Чазова И.Е. и др. Легочная гипертензия. Клинические рекомендации. Министерство здравоохранения Российской Федерации. 2016 г. http://www.fesmu.ru/SITE/files/editor/file/fpk_pps/rv29.pdf
[Chazova I.E. et al. Pulmonary hypertension. Clinical recommendations. Ministry of Health of the Russian Federation. 2016 year. http://www.fesmu.ru/SITE/files/editor/file/fpk_pps/rv29.pdf (in Russian).]
3. Черепанова Н.А. и др. Хроническая посттромбоэмболическая легочная гипертензия: новые возможности ведения пациента. Кардиология: Новости. Мнения. Обучение. 2015; 3 (6).
[Cherepanova N.A. et al. Khronicheskaia posttromboembolicheskaia legochnaia gipertenziia: novye vozmozhnosti vedeniia patsienta. Kardiologiia: Novosti. Mneniia. Obuchenie. 2015; 3 (6). (in Russian).]
4. Инструкция по применению лекарственного препарата для медицинского применения Адемпас. Регистрационный номер: ЛП-002639. Данная версия инструкции действует с 05.10.2017.
[Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Adempas. Registratsionnyi nomer: LP-002639. Dannaia versiia instruktsii deistvuet s 05.10.2017 (in Russian).]
5. Ghofrani HA et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med 2013; 369: 319–29.
6. Ghofrani HA et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 330–40. DOI: 10.1056/NEJMoa1209655
7. Evgenov OV et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5 (9): 755–68.
8. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol 2013; 31: 1064. DOI: 10.1038/nbt1213-1064b
9. Lewis J. Rubin et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1303–13 DOI: 10.1183/09031936.00090614
10. Gerald Simonneau et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45: 1293–1302. DOI: 10.1183/09031936.00087114
11. Hoeper MM et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017; 50: 1602425. DOI: 10.1183/13993003.02425-2016
12. Kim NH et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1801915. DOI: 10.1183/13993003.01915-2018
13. Delcroix M et al. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation 2016; 133: 859–71.
14. Madani M et al. The changing landscape of chronic thromboembolic pulmonary hypertension management. Eur Respir Rev 2017; 26: 170105. DOI: 10.1183/16000617.0105-2017
15. Voorburg JAI et al. Balloon Angioplasty in the Treatment of Pulmonary Hypertension Caused by Pulmonary Embolism. Chest 1988; 94 (Issue 6): 1249–53. DOI: 10.1378/chest.94.6.1249
16. Hiroki Mizoguchi et al. Refined Balloon Pulmonary Angioplasty for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension. Circulation: Cardiovascular Interventions. 2012; 5: 748–55. DOI: 10.1161/CIRCINTERVENTIONS.112.971077
17. Xavier Jais et al. Late Breaking Abstract – Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: results from the randomised controlled RACE study. Eur Respir J 2019; 54 (Suppl. 63): RCT1885. DOI: 10.1183/13993003.congress-2019.RCT1885
2. Chazova I.E. et al. Pulmonary hypertension. Clinical recommendations. Ministry of Health of the Russian Federation. 2016 year. http://www.fesmu.ru/SITE/files/editor/file/fpk_pps/rv29.pdf (in Russian).
3. Cherepanova N.A. et al. Khronicheskaia posttromboembolicheskaia legochnaia gipertenziia: novye vozmozhnosti vedeniia patsienta. Kardiologiia: Novosti. Mneniia. Obuchenie. 2015; 3 (6). (in Russian).
4. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Adempas. Registratsionnyi nomer: LP-002639. Dannaia versiia instruktsii deistvuet s 05.10.2017 (in Russian).
5. Ghofrani HA et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med 2013; 369: 319–29.
6. Ghofrani HA et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 330–40. DOI: 10.1056/NEJMoa1209655
7. Evgenov OV et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5 (9): 755–68.
8. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol 2013; 31: 1064. DOI: 10.1038/nbt1213-1064b
9. Lewis J. Rubin et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1303–13 DOI: 10.1183/09031936.00090614
10. Gerald Simonneau et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45: 1293–1302. DOI: 10.1183/09031936.00087114
11. Hoeper MM et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017; 50: 1602425. DOI: 10.1183/13993003.02425-2016
12. Kim NH et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1801915. DOI: 10.1183/13993003.01915-2018
13. Delcroix M et al. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation 2016; 133: 859–71.
14. Madani M et al. The changing landscape of chronic thromboembolic pulmonary hypertension management. Eur Respir Rev 2017; 26: 170105. DOI: 10.1183/16000617.0105-2017
15. Voorburg JAI et al. Balloon Angioplasty in the Treatment of Pulmonary Hypertension Caused by Pulmonary Embolism. Chest 1988; 94 (Issue 6): 1249–53. DOI: 10.1378/chest.94.6.1249
16. Hiroki Mizoguchi et al. Refined Balloon Pulmonary Angioplasty for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension. Circulation: Cardiovascular Interventions. 2012; 5: 748–55. DOI: 10.1161/CIRCINTERVENTIONS.112.971077
17. Xavier Jais et al. Late Breaking Abstract – Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: results from the randomised controlled RACE study. Eur Respir J 2019; 54 (Suppl. 63): RCT1885. DOI: 10.1183/13993003.congress-2019.RCT1885
[Chazova I.E. et al. Clinical recommendations for the diagnosis and treatment of pulmonary hypertension. Eurasian Association of Cardiology. 2019 year. http://cardio-eur.asia/media/files/clinical_recommendations/Klinicheskiye_rekomendatsii_Yevraziyskoy... (in Russian).]
2. Чазова И.Е. и др. Легочная гипертензия. Клинические рекомендации. Министерство здравоохранения Российской Федерации. 2016 г. http://www.fesmu.ru/SITE/files/editor/file/fpk_pps/rv29.pdf
[Chazova I.E. et al. Pulmonary hypertension. Clinical recommendations. Ministry of Health of the Russian Federation. 2016 year. http://www.fesmu.ru/SITE/files/editor/file/fpk_pps/rv29.pdf (in Russian).]
3. Черепанова Н.А. и др. Хроническая посттромбоэмболическая легочная гипертензия: новые возможности ведения пациента. Кардиология: Новости. Мнения. Обучение. 2015; 3 (6).
[Cherepanova N.A. et al. Khronicheskaia posttromboembolicheskaia legochnaia gipertenziia: novye vozmozhnosti vedeniia patsienta. Kardiologiia: Novosti. Mneniia. Obuchenie. 2015; 3 (6). (in Russian).]
4. Инструкция по применению лекарственного препарата для медицинского применения Адемпас. Регистрационный номер: ЛП-002639. Данная версия инструкции действует с 05.10.2017.
[Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Adempas. Registratsionnyi nomer: LP-002639. Dannaia versiia instruktsii deistvuet s 05.10.2017 (in Russian).]
5. Ghofrani HA et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med 2013; 369: 319–29.
6. Ghofrani HA et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 330–40. DOI: 10.1056/NEJMoa1209655
7. Evgenov OV et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5 (9): 755–68.
8. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol 2013; 31: 1064. DOI: 10.1038/nbt1213-1064b
9. Lewis J. Rubin et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1303–13 DOI: 10.1183/09031936.00090614
10. Gerald Simonneau et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45: 1293–1302. DOI: 10.1183/09031936.00087114
11. Hoeper MM et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017; 50: 1602425. DOI: 10.1183/13993003.02425-2016
12. Kim NH et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1801915. DOI: 10.1183/13993003.01915-2018
13. Delcroix M et al. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation 2016; 133: 859–71.
14. Madani M et al. The changing landscape of chronic thromboembolic pulmonary hypertension management. Eur Respir Rev 2017; 26: 170105. DOI: 10.1183/16000617.0105-2017
15. Voorburg JAI et al. Balloon Angioplasty in the Treatment of Pulmonary Hypertension Caused by Pulmonary Embolism. Chest 1988; 94 (Issue 6): 1249–53. DOI: 10.1378/chest.94.6.1249
16. Hiroki Mizoguchi et al. Refined Balloon Pulmonary Angioplasty for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension. Circulation: Cardiovascular Interventions. 2012; 5: 748–55. DOI: 10.1161/CIRCINTERVENTIONS.112.971077
17. Xavier Jais et al. Late Breaking Abstract – Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: results from the randomised controlled RACE study. Eur Respir J 2019; 54 (Suppl. 63): RCT1885. DOI: 10.1183/13993003.congress-2019.RCT1885
________________________________________________
2. Chazova I.E. et al. Pulmonary hypertension. Clinical recommendations. Ministry of Health of the Russian Federation. 2016 year. http://www.fesmu.ru/SITE/files/editor/file/fpk_pps/rv29.pdf (in Russian).
3. Cherepanova N.A. et al. Khronicheskaia posttromboembolicheskaia legochnaia gipertenziia: novye vozmozhnosti vedeniia patsienta. Kardiologiia: Novosti. Mneniia. Obuchenie. 2015; 3 (6). (in Russian).
4. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Adempas. Registratsionnyi nomer: LP-002639. Dannaia versiia instruktsii deistvuet s 05.10.2017 (in Russian).
5. Ghofrani HA et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med 2013; 369: 319–29.
6. Ghofrani HA et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 330–40. DOI: 10.1056/NEJMoa1209655
7. Evgenov OV et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5 (9): 755–68.
8. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol 2013; 31: 1064. DOI: 10.1038/nbt1213-1064b
9. Lewis J. Rubin et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1303–13 DOI: 10.1183/09031936.00090614
10. Gerald Simonneau et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45: 1293–1302. DOI: 10.1183/09031936.00087114
11. Hoeper MM et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017; 50: 1602425. DOI: 10.1183/13993003.02425-2016
12. Kim NH et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1801915. DOI: 10.1183/13993003.01915-2018
13. Delcroix M et al. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation 2016; 133: 859–71.
14. Madani M et al. The changing landscape of chronic thromboembolic pulmonary hypertension management. Eur Respir Rev 2017; 26: 170105. DOI: 10.1183/16000617.0105-2017
15. Voorburg JAI et al. Balloon Angioplasty in the Treatment of Pulmonary Hypertension Caused by Pulmonary Embolism. Chest 1988; 94 (Issue 6): 1249–53. DOI: 10.1378/chest.94.6.1249
16. Hiroki Mizoguchi et al. Refined Balloon Pulmonary Angioplasty for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension. Circulation: Cardiovascular Interventions. 2012; 5: 748–55. DOI: 10.1161/CIRCINTERVENTIONS.112.971077
17. Xavier Jais et al. Late Breaking Abstract – Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: results from the randomised controlled RACE study. Eur Respir J 2019; 54 (Suppl. 63): RCT1885. DOI: 10.1183/13993003.congress-2019.RCT1885
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.